| 李 莉,白晓兵,王景阳,王二雄,贾 娟.乌司他丁联合布地奈德治疗支气管哮喘急性发作期的临床疗效及对患者血清PDCD5、S1P、OPN水平的影响[J].,2019,19(18):3541-3545 |
| 乌司他丁联合布地奈德治疗支气管哮喘急性发作期的临床疗效及对患者血清PDCD5、S1P、OPN水平的影响 |
| Curative Efficacy of Ustardine and Budesonide in the Treatment of Acute Attack of Bronchial Asthma and Its Effectsthe Serum PDCD5, S1P and OPN Levels |
| 投稿时间：2019-01-24 修订日期：2019-02-18 |
| DOI：10.13241/j.cnki.pmb.2019.18.031 |
| 中文关键词: 乌司他丁 布地奈德 支气管哮喘急性发作期 程序化细胞死亡因子5 1-磷酸鞘氨醇 骨桥蛋白 |
| 英文关键词: Ulinastatin Budesonide Acute attack of bronchial asthma Programmed cell death factor 5 1- phosphosphingamine osteopontin |
| 基金项目:陕西省自然科学基金项目(13008085QH197)；陕西省自然科学基础研究计划资助项目（2019JM-513） |
|
| 摘要点击次数: 762 |
| 全文下载次数: 550 |
| 中文摘要: |
| 摘要 目的：探讨乌司他丁联合布地奈德治疗支气管哮喘急性发作期的临床疗效及对患者血清程序化细胞死亡因子5(PDCD5)、1-磷酸鞘氨醇(S1P)、骨桥蛋白(OPN)水平的影响。方法：选择2014年3月到2017年3月于我院进行治疗的170例支气管哮喘急性发作期患者作为研究对象，按照随机数表法分为观察组(n=90)和对照组(n=80)。对照组使用布地奈德治疗，观察组在对照组的基础上使用乌司他丁进行治疗。比较两组的临床疗效，治疗前后血清PDCD5、S1P、OPN水平、第 1 秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC水平的变化、临床症状改善情况及不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率为95.56%，明显高于对照组(71.25%，P＜0.05)；两组血清PDCD5、S1P、OPN水平较治疗前均显著降低(P＜0.05)，且观察组血清以上指标均明显低于对照组(P＜0.05)；两组FEV1、FVC、FEV1/FVC水平较治疗前均显著升高(P＜0.05)，观察组以上指标均明显高于对照组(P＜0.05)；观察组患者咳嗽、哮鸣音及胸闷气短消失时间均明显短于对照组(P＜0.05)；观察组不良反应总发生率为6.67%，显著低于对照组(18.75%，P＜0.05)。结论：乌司他丁联合布地奈德治疗支气管哮喘急性发作期患者的临床效果显著优于单用布地奈德治疗，可能与其有效改善患者血清PDCD5、S1P、OPN水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of ustardine and budesonide in the treatment of acute attack of bronchial asthma and its effects on the serum programmed cell death factor 5 (PDCD5), 1-sphingosine (S1P), osteopontin (OPN) levels. Methods: 170 cases of patients with acute episodes of bronchial asthma treated in our hospital from March 2014 to March 2017 were selected as the research objects, the patients were divided into the observation group (n=90) and the control group (n=80) according to the random number table method. The control group was treated with budesonide, and the observation group was treated with ulinastatin on the basis of control group. The clinical effects, changes of serum PDCD5, S1P, OPN levels, forced expiratory volume (FEV1), forced vital capacity (FVC), and FEV1/FVC levels before and after treatment, as well as the improvement of clinical symptoms and the occurrence of adverse reactions of the two groups were compared. Results: After treatment, the total effective rate of the observation group was 95.56%, which was significantly higher than that of the control group (71.25%, P < 0.05). The levels of PDCD5, S1P and OPN in the two groups were significantly lower than those before treatment (P<0.05), and the above serum indexes in the observation group were significantly lower than those in the control group (P<0.05). The levels of FEV1, FVC and FEV1/FVC in the two groups were significantly higher than those before treatment (P<0.05), and the above indicators in the observation group were significantly higher than those in the control group (P<0.05). The cough, asthma and short disappearance time in the observation group were significantly shorter than those in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 6.67%, which was significantly lower than that in the control group (18.75%, P<0.05). Conclusion: The clinical effect of ulinastatin combined with budesonide is significantly better than that of single budesonide treatment in the treatment of patients with acute bronchial asthma attack, which may be related to the effective improvement of patients' serum PDCD5, S1P and OPN levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
